Immunosuppression/chemotherapy regimens at presentation, n (%) | |
Chemotherapy for hematological malignancy with adjuvant corticosteroids | 67 (22.6) |
Corticosteroids in monotherapy | 44 (14.8) |
Graft rejection prophylaxis after solid organ transplantation | 36 (12.1) |
Chemotherapy for solid malignancy with adjuvant corticosteroids | 33 (11.1) |
DMARDs with adjuvant corticosteroids | 22 (7.4) |
Chemotherapy for solid malignancy | 16 (5.4) |
Chemotherapy for hematological malignancy | 12 (4.0) |
Corticosteroids and other immunosuppressantsa | 8 (2.7) |
DMARDs in monotherapy | 5 (1.7) |
Prophylaxis or treatment for GVHD after allogenic stem cell transplantation | 3 (1.0) |
Other combinationsb | 2 (0.7) |
None | 49 (16.5) |
Systemic corticosteroid exposure last 60 days prior to presentation, n (%) | |
Daily | 125 (42.1) |
Intermittent | 91 (30.6) |
No exposure to systemic corticosteroids | 79 (26.6) |
No information | 2 (0.7) |
Corticosteroid daily dosage in mg methylprednisolone at presentation, n = 292 | |
Median the day of P. jirovecii detection (q1-q3), n = 146 | 8 (4–20) |
Minimum, maximum | 0,120 |
Indications for corticosteroid administration among exposedc, n (%) | |
Immunosuppression for immunological disorders or graft rejection prophylaxis | 99 (46.3) |
Chemotherapy | 75 (35.0) |
Anti-emesis and other oncological indicationsd | 51 (23.8) |
Peritumoral oedema in primary and secondary intracranial tumors | 16 (7.5) |
Hematological and solid malignancies complicated by AIHA or ITP | 9 (4.2) |